BioSpace News Archive

NED Biosystems, a clinical-stage biotech company investigating solutions for a broad range of cancers, is pleased to announce Brian Leyland-Jones, BS, MBBS, PhD, FRACP, FRCPC, has been named Chairman of the Scientific Advisory Board.

Francis Medical, Inc. announced the appointment of Dr. Jonathan Jarow as the company’s chief medical officer Dr. Jarow will be leading Francis Medical’s clinical and regulatory efforts, including the VAPOR trials evaluating water vapor ablation as a minimally invasive treatment for prostate cancer.

Funded collaborative research effort strengthens the population simulation functionality in GastroPlus®

ANS-6637 is a new chemical entity selective ALDH2 Inhibitor with a mechanism of action expected to prevent craving and relapse for patients being treated for substance use disorders including alcohol use disorder.

Creative Medical Technology Holdings, Inc., a leading commercial stage biotechnology company focused on Urology, Neurology and Orthopedics using stem cell treatments, announced the successful clinical commercialization of StemSpine®.

Predictive Laboratories announces Kenneth Ward, M.D., laboratory director of Predictive Laboratories and chief executive officer of Juneau Biosciences; Rakesh Chettier M.S., director of biostatistics of Predictive Laboratories; and Hans Albertsen, Ph.D., chief scientific officer of Juneau Biosciences, have received the 2019 Endometriosis Special Interest Group Prize Paper in the “Best in Clinical/Population Science” category.

Medical Marijuana, Inc. (“the Company”) (OTC: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, announced today that its subsidiary Kannaway® is hosting a series of “Hemp for Humanity” events in Fukuoka, Osaka and Tokyo, Japan, this month.

Sensorion announced the last patient’s last visit in its Phase 2 clinical trial for SENS-111 investigated for the potential treatment of Acute Unilateral Vestibulopathy

Verona Pharma plc, a biopharmaceutical company focused on respiratory diseases, announces that it has randomized the last patient in its Phase 2b dose-ranging study evaluating the effect of nebulized ensifentrine as an add-on to treatment with a long acting bronchodilator in patients with moderate-to-severe chronic obstructive pulmonary disease

Myovant Sciences announced the formation of Female Forward Together, a cross-sector coalition bringing together expertise in healthcare, research, data science, digital health, and advocacy to improve women’s health.